⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2587299 | 0.97 | — | — | |
| SCHEMBL20203375 | 0.90 | — | — | |
| SCHEMBL27474409 | 0.88 | DNM1 (0.60) | — | |
| SCHEMBL29012275 | 0.88 | DNM1 (0.60) | — | |
| SCHEMBL29363073 | 0.88 | DNM1 (0.60) | — | |
| SCHEMBL5536819 | 0.88 | DNM1 (0.60) | — | |
| SCHEMBL27297974 | 0.88 | DNM1 (0.60) | — | |
| SCHEMBL2585592 | 0.79 | — | — | |
| SCHEMBL5404334 | 0.79 | TSHR (0.50) | — | |
| SCHEMBL1785109 | 0.76 | CA12 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20220049292-A1 | MULTIPLEXED FLUORESCENT DETECTION OF ANALYTES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-10558119-B2 | Composition for coating resist pattern | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3522323-A1 | FREQUENCY RESPONSE CONTROL SYSTEM WITH CLIPPING PARAMETER DETERMINATION | Johnson Controls Technology Company (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3089974-B1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA SAS (FR) | 2019-02-20 | — | — | EP | disclosed |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-01-17 | — | — | US | disclosed |
| US-20180149977-A1 | COMPOSITION FOR COATING RESIST PATTERN | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-05-31 | — | — | US | disclosed |
| US-8772268-B2 | Bisphosphonamidate prodrugs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130090311-A1 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011139791-A2 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-11-10 | — | — | WO | disclosed |
| US-7173020-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2006099313-A2 | PHOSPHATE CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006037090-A2 | DRUG-PHOSPHATE CONJUGATES AS PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2006-04-06 | — | — | WO | disclosed |
| EP-1268493-B1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050171060-A1 | Phosphoramidates and methods therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-04 | — | — | US | disclosed |
| US-6903081-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1268493-A1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020004594-A1 | Phosphoramidates and methods therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-01-10 | — | — | US | disclosed |
| WO-2001074827-A1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2001-10-11 | — | — | WO | disclosed |